Medical Condition

rhabdomyosarcoma

Total Trials

9

Recruiting Now

9

Trial Phases

Phase 1, Phase 1, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for rhabdomyosarcoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — rhabdomyosarcoma Clinical Trials

How many clinical trials are currently recruiting for rhabdomyosarcoma?

ClinicalMetric currently tracks 9 actively recruiting clinical trials for rhabdomyosarcoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for rhabdomyosarcoma?

rhabdomyosarcoma research spans Phase 1 (6 trials), Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a rhabdomyosarcoma clinical trial?

Eligibility criteria for rhabdomyosarcoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

University of Rochester 1 trial

Sun Yat-sen University 1 trial

Children's National Research Institute 1 trial

ITM Solucin GmbH 1 trial

New York Medical College 1 trial

Recruiting Clinical Trials

NCT07054944

Recruiting

Tumor-Lymph Node Mapping

University of Rochester

View Trial →

NCT07584499 Phase 1

Recruiting

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors

Sun Yat-sen University

View Trial →

NCT07172958 Phase 1

Recruiting

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

Children's National Research I...

View Trial →

NCT06441331 Phase 1

Recruiting

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Enrollment

20 pts

Location

United States, Franc...

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

New York Medical College

View Trial →

NCT04625907 Phase 1, Phase 2

Recruiting

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Enrollment

1,672 pts

Location

Australia, Austria, ...

Sponsor

University of Birmingham

View Trial →

NCT04897321 Phase 1

Recruiting

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

St. Jude Children's Research H...

View Trial →

NCT06836492 Phase 3

Recruiting

A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.

Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Through Spatial Proteome Analysis Using Mass Spectrometry

Related Conditions

neuroblastoma (4) wilms tumor (4) ewing sarcoma (3) germ cell tumor (2) hepatoblastoma (2) pediatric solid tumors (1) sarcoma (1) head and neck squamous cell carcinoma hnscc recurrent metastatic r m (1) nasopharyngeal carcinoma (1) lymphoepithelial carcinoma (1) medulloblastoma (1) atypical teratoid rhabdoid tumors (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology